Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Marisa Cruz_2023
Marisa Cruz, in an insightful conversation with PharmaShots, discusses the Empatica Health Monitoring Platform (EHMP)
Shots:  Marisa Cruz, MD, and Chief Medical Officer at Empatica, exchanged thoughts with PharmaShots on the revolutionary Empatica Health Monitoring Platform (EHMP)   Approved by the FDA in Nov’2022, EHMP leverages a cloud-based online portal to collect continuous and seamless physiological data from home and clinical setting   While conversing in great depth about Empatica’s EmbracePlus smartwatch,…
November 2, 2023
VIEWPOINTS_Liz Hurlburt_2023
Liz Hurlburt sheds light on DefenCath, a one of the kind, catheter lock solution
Shots:  Liz Hurlburt, Executive Vice President of Clinical & Medical Affairs at CorMedix discusses the revolutionary prospects of DefenCath, a catheter lock solution to prevent CRBSIs in patients receiving hemodialysis via. CVC   Liz sheds light on a serious unmet need for patients affected with catheter-related bloodstream infections. CRBSIs affect approximately 250,000 people annually who receive…
October 31, 2023
VIEWPOINTS_Catherine Liao_2023
A stirring conversation between Catherine Liao and PharmaShots on SphygmoCor Technology
Shots:  Catherine Liao, Chief Strategy Officer of CardieX, discusses the recent partnership between CardieX’s subsidiary ATCOR and Datacubed Health   Catherine delves deep into the growing dependence on decentralized clinical trials in the healthcare community and cites a few challenges in the study that come with it   Catherine stresses the potential of SphygmoCor technology while discussing…
October 30, 2023
VIEWPOINTS_Kyle Forcier_2023
In a gripping conversation with PharmaShots, Kyle Forcier addresses the ways to avoid the challenges of the 340B program
Shots:  Kyle Forcier, Sr. Director of Life Science Product Marketing at Model N, addresses the challenges of the 340B program and ways manufacturers can mitigate them and emerge stronger   340B, a US federal government plan, enables eligible healthcare organizations and covered entities to receive outpatient drugs from drug manufacturers at significantly low prices   Kyle recalls…
October 23, 2023
VIEWPOINTS_Björn Mellgård_2023
Björn Mellgård shares insights from the Pivotal Phase III data of TAK-755 for congenital thrombotic thrombocytopenic purpura (cTTP)
Shots:  Björn Mellgård Vice President and Global Program Lead, TTP Program, Takeda, shares insights from the P-III data of TAK-755 for the treatment of cTTP   Björn eloquently shares the highlights of the study design for TAK-755, safety and efficacy outcomes, and goes on to share an update from the P-IIIb continuation trial evaluating TAK-755   With…
October 19, 2023
VIEWPOINTS_Sujay Jadhav_2023
Sujay Jadhav converses about VeraSite, a recently launched subscription-based tool for clinical trial site selection
Shots:  In an insightful interview with PharmaShots, Sujay Jadhav, CEO of Verana Health, discusses VeraSite, a recently launched subscription-based tool for clinical trial site selection   To gather real-world data, Verana Health leverages the VeraQ population health data engine and transforms the structured and unstructured data into curated disease-specific modules called QData   Currently available in the…
October 17, 2023
VIEWPOINTS_Nathan McCutcheon_2023
Nathan McCutcheon shares highlights of Qpex Biopharma’s acquisition by Shionogi
Shots:  Nathan McCutcheon, President, and Chief Executive Officer of Shionogi, shares the highlights of the recent acquisition of Qpex Biopharma by Shionogi   Nathan believes that Qpex’s specialized expertise and extensive experience in chemistry and molecular design are sure to strengthen and be useful for the combined antibiotic pipeline   The acquisition provides Shionogi exclusive development, manufacturing,…
October 16, 2023
VIEWPOINTS_Robert Connelly_2023
Robert Connelly shares the highlights of the post-merger between Elicio Therapeutics & Angion Biomedica Corp.
Shots:  Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies  Robert recapitulates data presented at ASCO…
October 9, 2023
VIEWPOINTS_Samantha Kerr_2023
Samantha Kerr shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+)
Shots: Samantha Kerr, Chief Scientific Officer, Merz Aesthetics shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+) Samantha says, for Belotero Balance (+), Merz Aesthetics has already submitted the data as a supplemental Premarket Approval Application (sPMA) with the FDA and plans to submit the data as…
October 5, 2023
Load more